Search filters

Filters
Clear All

Phase

  • 1
  • 10
  • 11
  • 6
  • 3
  • 25
  • 78
  • 39
  • 4
  • 2
  • 73

Found 79 Lymphocytic Leukemia, Acute trials

A listing of Lymphocytic Leukemia, Acute medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Managed Access Program (MAP) to provide access to CTL019  for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
99 years or below
All genders
The purpose of this Treatment Plan is to allow access to tisagenlecleucel (CTL019) for eligible patients diagnosed with acute lymphoblastic leukemia (ALL) or large b-cell lymphomas who are unable to receive commercially manufactured product due to failure of the incoming apheresis material or outgoing product to meet the commercial specifications …
99 years or below
All genders
Phase 1
Subjects with breast cancer starting treatment with anthracyclines/trastuzumab will be enrolled and their risk of cardiotoxicity calculated. If elevated risk, they will be randomized to intervention with carvedilol for 1 year vs usual care. Low risk subjects will be usual care. All subjects will be followed with serial echo, survey, …
99 years or below
All genders
Phase 2
This study will evaluate using hydroxychloroquine (HCQ) along with binimetinib as an effective method for treating cancer. All patients will receive binimetinib at a standard dose approved for other cancers. The dose of HCQ will also be fixed based on ongoing phase I studies. Eligible subjects will have lung cancer …
 A Pilot Study to Evaluate the Effect of CT1812 Treatment on A-beta Oligomer Displacement into CSF in Subjects with Mild to Moderate Alzheimer's Disease
99 years or below
All genders
Phase 1
Cognition Therapeutics is developing an oral formulation of CT1812 to treat AD and mild cognitive impairment. This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD, sponsored by the NIH. The primary purpose of this study is to evaluate target engagement of …
99 years or below
All genders
Phase 1
Multicenter, open-label study of PT-112 in patients with relapsed/refractory MM. The study will be conducted in two parts. The first part of the study involves dose-escalation, in which successive cohorts of patients will receive escalating doses of PT-112 until the maximum tolerated dose (MTD) is reached. The second part of …
 GENETICS  MECHANISMS AND CLINICAL PHENOTYPES OF ARRHYTHMOGENIC CARDIOMYOPATHY
1 years - 99 years
All genders
Phase 4
The well-established, consistent and precise phenotyping developed in the previous ARVC Registry (and published as the Modified Task Force Criteria), with a comprehensive primary genotyping approach, search for genetic modifiers, and biomarker analysis will fulfill the long-term goals of this proposal to identify the genetic basis of all forms of …
 An Open-Label Phase 2 Proof or Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471
17 years - 65 years
All genders
Phase 2
This is an open-label study of 12 months of dosing with ACH-0144471. The study will enroll patients with biopsy-confirmed C3G or IC-MPGN who meet eligibility criteria for this study. There will be a multi-step screening process. At the initial screening visit, all screening eligibility assessments, except the renal biopsy, will …
99 years or below
All genders
Phase 3
This is a randomized, double-blind, placebo-controlled, multicenter study in patients with primary cold agglutinin disease (CAgD) without a recent history of blood transfusion. Eligible patients will receive study drug (BIVV009 or placebo) and undergo safety and efficacy assessments for 6 months (26 weeks) during Part A. Following completion of the …
 Towards predicting the analgesic response to ibuprofen following third-molar extraction
18 years - 64 years
All genders
NSAIDs like ibuprofen are pain relievers that are commonly used to reduce pain after dental procedures.  Patients who have their impacted third molar teeth taken out usually experience pain one to three hours after surgery and require pain relievers for at least 2 days. Most people (about 70-90%) experience good …